NZ598439B - Adhesive bandage - Google Patents
Adhesive bandage Download PDFInfo
- Publication number
- NZ598439B NZ598439B NZ598439A NZ59843912A NZ598439B NZ 598439 B NZ598439 B NZ 598439B NZ 598439 A NZ598439 A NZ 598439A NZ 59843912 A NZ59843912 A NZ 59843912A NZ 598439 B NZ598439 B NZ 598439B
- Authority
- NZ
- New Zealand
- Prior art keywords
- bandage
- absorbent pad
- pad
- channels
- layer
- Prior art date
Links
- 239000000853 adhesive Substances 0.000 title claims abstract description 41
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 41
- 239000002250 absorbent Substances 0.000 claims abstract description 132
- 230000002745 absorbent Effects 0.000 claims abstract description 132
- 239000010410 layer Substances 0.000 claims description 117
- 239000012790 adhesive layer Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000835 fiber Substances 0.000 claims description 4
- 229920002994 synthetic fiber Polymers 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 description 40
- 208000027418 Wounds and injury Diseases 0.000 description 40
- 239000002585 base Substances 0.000 description 38
- -1 polyethylene Polymers 0.000 description 32
- 239000012530 fluid Substances 0.000 description 17
- 239000004743 Polypropylene Substances 0.000 description 16
- 239000002674 ointment Substances 0.000 description 16
- 229920001155 polypropylene Polymers 0.000 description 16
- 239000000463 material Substances 0.000 description 14
- 229920000139 polyethylene terephthalate Polymers 0.000 description 14
- 238000004049 embossing Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000001814 pectin Substances 0.000 description 6
- 229920001277 pectin Polymers 0.000 description 6
- 235000010987 pectin Nutrition 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005299 abrasion Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000280 densification Methods 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000000416 hydrocolloid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004026 adhesive bonding Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FTALTLPZDVFJSS-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl prop-2-enoate Chemical compound CCOCCOCCOC(=O)C=C FTALTLPZDVFJSS-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- FWWXYLGCHHIKNY-UHFFFAOYSA-N 2-ethoxyethyl prop-2-enoate Chemical compound CCOCCOC(=O)C=C FWWXYLGCHHIKNY-UHFFFAOYSA-N 0.000 description 1
- HFCUBKYHMMPGBY-UHFFFAOYSA-N 2-methoxyethyl prop-2-enoate Chemical compound COCCOC(=O)C=C HFCUBKYHMMPGBY-UHFFFAOYSA-N 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003377 metandienone Drugs 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0206—Adhesive bandages or dressings with fluid retention members with absorbent fibrous layers, e.g. woven or non-woven absorbent pads or island dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0223—Adhesive bandages or dressings with fluid retention members characterized by parametric properties of the fluid retention layer, e.g. absorbency, wicking capacity, liquid distribution
Abstract
Patent 598439 An adhesive bandage has a backing layer with an absorbent pad attached to it with adhesive. The pad has raised tufted regions separated by lower channel regions of a greater density than the raised regions. Each of the tufted regions is a polygon of four to eight sides.
Description
Received by IPONZ 25 July 2012
NEW ZEALAND
PATENTS ACT, 1953
COMPLETE SPECIFICATION
ADHESIVE BANDAGE
We,]OHNSON &jOHNSON CONSUMER COMPANIES, INC, a corporation of the State
of Newjersey, United States of America, of Grandview Road, Skillman, New Jersey 08558,
United States of America, do hereby declare the invention for which we pray that a patent may be
d to us, and the method by which it is to be performed, to be ularly described in and
by the following statement:
Received by IPONZ 25 July 2012
ADHESIVE BANDAGE
FIELD OF THE INVENTION
The present invention relates to an adhesive bandage to be applied onto the skin,
ularly an adhesive bandage with an absorbent pad having tufted regions
surrounded and separated by a network of interconnecting channels recessed in the
surface of the absorbent pad.
OUND OF THE INVENTION
There are many types ofwounds to the human body. They may be open or
. Open wounds include incisions or incised wounds, lacerations, abrasions,
puncture wounds and ation wounds. Closed wounds e contusions (bruises),
hematomas and crushing injuries. Depending on the ty of the wound, certain
wounds may require closing via sutures and the like, followed by topical application of
a wound dressing to protect the wound from dirt and further damage by contact.
rly, wounds due to medical surgical procedures typically require application of a
wound dressing subsequent to surgery to protect the wound.
As there are different types of wounds to the body, so are there different types
of dressings for application to such wounds. In certain dressings, absorbent structures,
e. g. pads, may be used to absorb exudates from the wound. Other wound dressings may
be free of such absorbent pads. For e, US 3,053,252 discloses bandages where
non—absorbent support surfaces or edges project beyond the absorbent surface towards
the wound site to form an embossed pattern of absorbent areas and non—absorbent
support surfaces. US 4,781,710 discloses es that utilize pads having tufted
regions surrounded by channels. The channels require both a transport region and a
storage region, where density of the transport region is r than that of the storage
region. US 387 relates to absorbent products adapted to absorb body fluids. Such
products utilize a loosely compacted cellulosic s batt having a plurality of spaced,
relatively narrow, dense lines in the general plane of the batt. The batts have a non-
uniform density where the areas ofthe batt adjacent the lines cover or obscure the lines
Received by IPONZ 25 July 2012
due to modified batt regions of lesser density adjacent the lines than the average density
of the batt.
SUMMARY OF THE INVENTION
The present invention relates to bandages for application to abrasions or cuts in
the skin, where the bandage es a backing layer having a first e and a second
surface opposite the first surface, an adhesive layer applied to at least a portion of the
second surface of the backing layer; and an absorbent pad associated with the backing
layer. The absorbent pad includes a first surface facing the backing layer and that has a
first e area, and a second surface opposite the first e and that has a second
surface area. The absorbent pad comprises a plurality of tufted regions, where the
shape ofthe tufted regions is a n having from four to eight sides. The tufted
regions are surrounded and separated by a first network of interconnecting linear
channels recessed in the second surface of the absorbent pad. The channels comprise
and are defined by channel sidewalls extending away from the second surface and into
the core body ofthe absorbent pad and terminating in a first e of a channel base
region extending between the channel sidewalls. The absorbent pad has a ess
defined by the distance between the first and second surfaces of the absorbent pad. The
tufted regions have a substantially uniform first y, while the channel base region
has a substantially uniform second density that is greater than the substantially uniform
first density of the tufted regions. The channel base region has a thickness defined by
the distance between the first surface of the chamel base region and a second surface of
the channel base region opposite the first surface. The network of interconnecting
channels is e to the user of the es.
Accordingly, in a first aspect the invention provides an ve bandage for
application to abrasions or cuts in the skin, comprising:
a backing layer comprising a first surface and a second surface opposite said
first surface,
an adhesive layer applied to at least a portion of said second surface of said
backing layer; and
an absorbent pad ated with said backing layer, said absorbent pad
comprising,
Received by IPONZ 25 July 2012
a first surface facing said second surface of said backing layer and having a
first surface area,
a second surface opposite said first surface and having a second surface
area; and
a core body bounded by said first and second surfaces;
said absorbent pad comprising a plurality of tufted regions surrounded and
separated by a first network of interconnecting linear channels ed in said
second surface of said absorbent pad, said channels comprising channel
lls extending away from said second e and into said core body of
said absorbent pad and terminating in a first e of a channel base region
extending between said l sidewalls,
wherein the absorbent pad is free of slits or perforations uniformly buted
throughout the absorbent pad that would allow the adhesive layer to contact the wound
surface;
wherein the shape of each of said tufted regions is a polygon having from four to eight
sides, said tufted regions have a substantially m first density, said channel base
regions have a substantially uniform second density greater than said substantially
uniform first density of said tufted regions and said network of channels is visible.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will now be bed in greater detail with reference to
ments represented in the drawings.
is a perspective View of an embodiment of an adhesive bandage of the
present invention;
is a cross—sectional View of the ve bandage illustrated in
taken along line 2a———2a;
is a cross—sectional side view of an adhesive bandage similar to the
bandage as shown in where the second surface ofthe absorbent pad comprises a
covering layer;
is a top View of a first embodiment ofthe absorbent pad depicted in
taken perpendicular to the second surface of the bandage;
Received by IPONZ 25 July 2012
is a cross-sectional side View taken along line 3b--—3b of the pad
embodiment illustrated in ;
is a sectional side view of a second embodiment of an absorbent
pad used in bandages of the present invention;
is a cross-sectional side view of one embodiment of a bandage
according to the present ion utilizing the absorbent pad depicted in ;
is a cross-sectional side view of r ment of a bandage
according to the present invention utilizing the absorbent pad depicted in ;
is a ctive View of the bandage depicted in as seen from
the first side of the backing layer of the bandage;
is a view of another embodiment of an absorbent pad used in bandages
of the present invention; and
is a cross-sectional side View of another embodiment of an adhesive
bandage of the present invention.
DETAILED DESCRIPTION OF THE ION
Bandages according to the present invention e a backing layer having a
first surface facing away from the skin and a second surface, opposite the first surface,
and facing the skin. The backing layer may have various shapes, e. g. rectangular,
square, oval, circular, ovoid, oblong, etc. The shape of the bandage is defined by the
shape ofthe backing layer. The backing layer may be thin, highly flexible or
deformable, water—impervious, and clear or opaque. In general, the backing layer’s
thickness should fall within the range of 0.05 to 0.20 millimeter to achieve the forming
and flexing characteristics desired.
A hylene film may be used as the backing layer, and particularly effective
results may be ed with stretchable, meric films formed ofpolyurethane,
which has the further advantage of gas (including water vapor) transmissibility. It is to
be understood, however, that other flexible, water insoluble polymeric films known in
the art may be used. Furthermore, the backing layer may be formed from closed—cell
polymeric foam, particularly one with an integral skin covering the side facing away
Received by IPONZ 25 July 2012
from the skin of the user. Foam layers formed ofpolyurethane or polyethylene are
suitable, while other polymeric foams having similar properties may be used. In
addition, the backing layer may be made from other polyolefins, vinyl polyethylene
acetate, textile non-woven fabrics, rubber, or other materials known in the bandage art.
Polymers used to make backing layers used in es of the present invention may
exhibit Viscosity of about 500 to 500,000 centipoises at temperatures of about 190°C, or
about 1,000 to 30,000 centipoises at temperatures of about 190°C, or about 3,000 to
,000 centipoises at temperatures of about 190°C. The backing layer may be
eable to , but permeable to gas, which allows the wound and the skin to
which the bandage of the present invention is adhered to breathe. In one embodiment,
the backing layer may have pores of such a size that will allow only the passage of
gases, which have molecules of extremely small size. Finally, one can conceive of a
backing layer that is perforated for more ventilation of the skin. Perforations may be
circular in area and have a range of diameters, such as from about 0.1 to about 0.8
eters. However, the g layer may be totally impermeable to gases, when
necessary.
Bandages of the present invention comprise an absorbent pad associated with
the backing layer. As used herein, “associated with the backing layer” means that the
ent pad is affixed either directly or indirectly to the backing layer so that it will
not become separated from the backing layer during normal use. Association may be
accomplished by applying an adhesive layer between the second surface of the backing
layer and first surface of the absorbent pad, y adhesively bonding the absorbent
pad directly to the g layer. The absorbent pad also may be associated with an
intermediate layer, which in turn is associated with the backing layer, thus indirectly
associating the absorbent pad to the backing layer via the intermediate layer.
Association also may be accomplished by other known means such as ultrasonic
welding.
The absorbent pad includes a first surface facing the second surface of the backing
layer, and that has a first surface area, and a second e opposite the first surface
and facing the skin, and that has a second e area. The shape of the absorbent pad
used in bandages of the present invention is a polygon having from four to eight sides
and is sized to cover less area than the backing layer so that, in use, the adhesive layer
on the backing layer is in t with the user’s skin, but preferably does not contact
Received by IPONZ 25 July 2012
the wound e. As can be seen in Figures 1-6, the absorbent pad is free of slits or
perforations uniformly distributed throughout the absorbent pad that would allow the
adhesive layer to contact the wound surface. In certain embodiments, the absorbent pad
is free of slits or perforations that would allow the adhesive layer to contact the wound
surface.
In certain embodiments the absorbent pad will have from 5 to 7 sides. The
absorbent pad may be a fibrous matrix comprising materials selected from the group
consisting of threads, yarns, nets, laces, felts and nonwovens. The basis weight of the
materials selected as the absorbent pad in bandages of the present invention may be any
of those used conventionally to make absorbent pads for es utilized in
applications similar to those of the present invention. For example, the basis weight of
the material may be from about 3.0 oz/yd2 to about 5.5 oz/ydz, although the invention is
not limited as such.
The absorbent pad may be made from any type of material commonly used in
the art in forming such pads for use in bandages. Materials that may be used include
cellulose fiber gauzes, y cross-linked tissue structures, and other fibrous pads
comprising l or synthetic materials such as cotton, polyethylene terepthalate
(PET), polypropylene (PP), or blends e rayon and polyolefins, or other materials
that are absorbent and that are capable ofbeing embossed to form the network of
onnecting channels recessed in the surface of the absorbent pad. In certain
embodiments, the absorbable pad is not degradable in water.
The absorbent pad comprises a ity of tufted regions surrounded and
separated by a first network of interconnecting channels recessed in the second surface
ofthe absorbent pad. Tufted regions are understood to be substantially undensified, i.e.
relatively low density s compared to the density of the channel base regions. The
term “channels” refers to those recessed s which separate and surround the tufted
regions. The first and second surfaces of the tufted s are coincident with the first
and second es of the absorbent pad, respectively. The absorbent pad has a
thickness defined by the maximum distance between the first and second surfaces of
the absorbent pad. Typically, the thickness of the absorbent pad may range from about
0.3 millimeters to about 2.5 millimeters.
Received by IPONZ 25 July 2012
The interconnecting channels recessed in the second surface ofthe absorbent
pad are linear and comprise and are defined by channel sidewalls extending away from
the second surface and into the core body of the absorbent pad and terminating in a first
surface of a channel base region extending n the channel sidewalls. The channel
base region further has a second surface opposite the first surface, and a thickness
defined by the distance between the first and second es ofthe channel base
region. In certain embodiments, a second network of interconnecting channels is
recessed into the first surface of the ent pad. The second network of
interconnected channels may be in alignment with the first network of interconnecting
ls found in the second surface of the absorbent pad. The channels in the first
surface of the absorbent pad comprise and are defined by channel sidewalls extending
away from the first surface and into the core of the absorbent pad and terminating in the
second surface ofthe channel base region, which extends between the channel
sidewalls in the first surface of the absorbent pad.
The tufted regions have a substantially uniform first density. By “substantially
uniform first density”, it is meant that the density of the tufted region adjacent the
channels is substantially the same as the average density of the tufted region across the
entire area of the tufted region, such that the ls are not ed by the tufted
region adjacent the channel. The channel base region has a ntially uniform
second density that is greater than the substantially uniform first density of the tufted
s. By “substantially uniform second y”, it is meant that the density of the
channel base regions is substantially the same throughout the channel base region. In
some ments, the second density of the channel base region is about 12 times or
less greater than the first density of the tufted region, or from 1.1 to about 10 times
greater than the y of the tufted s. In some embodiments, the substantially
uniform first density of the tufted regions is from about 0.082 grams/cubic centimeter
to about 0.17 grams/cubic centimeter. In some embodiments, the substantially m
second density ofthe channel base regions is from about 0.11 grams/cubic centimeter
to about 0.96 grams/cubic centimeter. The network ofrecessed, interconnecting
channels may comprise from about 5 to about 20 percent of the surface area ofthe
surface of the absorbent pad, or from about 10 to about 15 percent of the e area of
the surface of the absorbent pad. This is whether the channels are present on one
surface or both surfaces of the pad.
Received by IPONZ 25 July 2012
The thickness of the channel base region may vary from about 0.1 millimeters
to about 1.5 millimeters, depending on the depth of the channels and whether both
surfaces or only one surface of the ent pad comprise channels recessed therein.
In addition to the substantially uniform first density of the tufted regions, the channels
have a width and depth such that the network of interconnecting channels is visible to
the user. By “visible”, it is meant that the network of interconnecting channels is
distinguishable from the tufted regions when the bandage is observed by the user at
distances normally encountered when applying the bandage to the skin or wound, e.g.
from about 6 to about 24 inches, or from about 6 to about 12 inches.
Interconnecting channels in the absorbent pad serve a number of functions.
Interconnecting channels function to transport low viscosity fluid, 6.g. wound exudates,
away from the wound surface by wicking action. As used herein, low viscosity fluids
are those with viscosities of less than 50,000 centipoises. The channel base regions, due
to their high density relative to the tufted regions, have smaller capillaries between their
fibers and are not able to absorb as much fluid as the lower density tufted regions.
Thus, channel base regions provide relatively fast wicking. The tufted regions have a
density less than the density of the channel base regions and, therefore, have larger
aries n their fibers than the channel base regions. This gives the tufted
regions the tendency to absorb more liquid than the l base regions. In use, low
Viscosity liquid which is deposited onto the absorbent pad is absorbed to some degree
by the tufted regions. In bandages of the present ion, tufted regions adjacent to
the area where the low viscosity liquid is deposited may not be able to absorb the liquid
fast enough to prevent “puddling” of the liquid on the absorbent pad, which antly
may give the user an uncomfortably wet feeling or cause skin irritation. The excess
liquid may enter the interconnectng ls, which may then direct the liquid to other
tufted s of the absorbent pad that may be less saturated, such that they will accept
and absorb the excess low viscosity liquid.
Another function of the interconnecting channels is to serve as a e depot
for high viscosity fluids. As used herein, high viscosity fluids are those with viscosities
of greater than 50,000 centipoises. If a user places a high viscosity nt, balm,
emollient, unguent, cream or salve on the wound site, and then places a standard pad
with a m density throughout its structure in t with the high ity fluid,
the fluid may spread from the wound site to portions of the pad that do not cover the
Received by IPONZ 25 July 2012
wound. If, however, a user places a high Viscosity ointment, balm, emollient, unguent,
cream or salve on the wound site, and then places es of the present invention in
t with the high ity fluid, the fluid may flow from the lower density tufied
regions to the relatively higher density channel base regions in the interconnecting
channels. In this way, the high Viscosity fluid may be maintained at the site of the
wound.
Yet another fiinction of the network of interconnecting channels is to provide a
Visual cue to the user. The term “visual cue”, as used herein, refers to visual
information, e.g. the way a product or portion of a product appears to the user, which is
used in connection with identifying a function or functions of the product. With respect
to bandages ofthe present invention, the visual cue is as to the function of the channels
in transporting low viscosity fluid away from the wound surface by wicking action,
and/or in serving as a storage depot for high viscosity fluids. Accordingly, the network
of interconnecting channels is Visible, as defined above. In some embodiments, the
width ofthe channels is from about 0.2 millimeters to about 0.6 millimeters or from
about 0.3 millimeters to about 0.45 millimeters, and the depth is from about 0.02 to
about 2.0 millimeters, or fiom about 0.04 to about 1.1 millimeters. In certain
embodiments, at least the first network of interconnecting ls recessed in the
second surface of the absorbent pad is visible to the user when observed from the
second surface of the absorbent pad. In other embodiments, both first and second
networks of interconnecting channels recessed in the first and second surfaces of the
absorbent pad, respectively, are Visible to the user when observed from the respective
surface. In one embodiment, the second network of interconnecting channels recessed
in the first surface of the absorbent pad may be visible to the user through the backing
layer, where the backing layer is transparent or translucent. In r ment, the
backing layer may m to the network of interconnecting channels due to the
process for making the bandage. In this embodiment, the g layer itself comprises
the k of interconnecting channels recessed in the first surface of the backing
layer, as shown herein.
In certain embodiments of the t invention the bandage may r
comprise an intermediate layer disposed between the backing layer and the absorbent
pad. The intermediate layer lly may be used where the backing layer is
transparent or translucent. In such bandages, the intermediate layer may be of a color
Received by IPONZ 25 July 2012
similar to skin of the user and may be used to mask the appearance of the absorbent pad
to the user, which pad may include exudates from the wound, including blood. When
used, such intermediate layers may be made from materials known to those skilled in
the art for similar use. The intermediate layer can be made from any type of material
commonly used in the art in forming adhesive bandages. In some ments, the
intermediate layer can be made from, for example, plastic g materials such as
those sold under the tradename Delnet, available from Delstar logies, Inc.,
Middletown, DE.
In certain embodiments of the present invention, the second surface, i.e. the
skin-facing surface, of the absorbent pad comprises a covering layer affixed thereto.
When present, the covering layer is considered as an integral component of the second
surface of the absorbent pad and the network of interconnected channels is embossed
into the absorbent pad after application of the ng layer to the absorbent pad. As
such, the covering layer also comprises the network of onnecting channels
recessed in the skin—facing surface. The covering layer provides additional protection to
the wound and, where the absorbent pad is fibrous, prevents fibers from sticking to the
wound or obscuring the channels. The ng layer is permeable to exudates to allow
passage of the exudates from the wound to the absorbent pad. Thus, the covering layer
may include perforations. The covering layer may be made of, for example, plastic
netting materials such as those sold under the tradename Delnet, available from r
logies, Inc., town, DE.
In general, any of a variety of pressure—sensitive adhesives can be ed in the
present invention as the adhesive layer to bond the absorbent pad to the backing layer
and to adhere the bandage to the skin. In particular, pressure-sensitive ves that
are biocompatible with human skin are lly utilized. Moreover, an adhesive used
in the present invention may be either generally water soluble, or generally insoluble or
dispersible in an aqueous environment. For instance, one commercially available
dispersible pressure—sensitive adhesive is sold under the trade name of HL—94l S-X and
is available from H.B. Fuller Company. Another suitable adhesive includes about 10-
75% by weight of a polyalkyloxazoline polymer, 10-75% by weight of a functional
diluent comprising a hydroxy compound or a carboxylic acid compound, and 5-50% by
weight of a tackifier.
Received by IPONZ 25 July 2012
The water—dispersible polymeric component can include, for example,
surfactants such as poly(ethylene oxide) alkylphenyl ethers, such as those sold under
the trade names IGEPALCO and IGEPAL.CA (available from Rhone-Poulenc, Inc.);
poly(ethylene oxide) lauryl, cetyl, and oleyl ethers such as those sold under the trade
name BRIJ (available from ICI Americas, Inc); p01y(ethylene oxide) laurate;
poly(ethylene oxide) oleate; sorbitan oleate; ethylene oxide/propylene oxide block
copolymers such as those sold under the trade names PLURONIC and TETRONIC
(available from BASF Corporation); and organic phosphate , such as those sold
under the trade name GAFAC PE—S 1 0 (available from International Specialty
ts). Examples of other components include, but are not limited to, p01y(acrylic
acid); poly(vinyl alcohol); p01y(N—viny1 pyrrolidone); crylamide);
p01y(alkoxya1kyl (meth)acrylates), such as 2-ethoxy ethyl acrylate, xy ethyl
methacrylate, 2—(2—ethoxyethoxy) ethyl acrylate, and 2—methoxy ethyl acrylate
(available from SARTOMER Company, Inc); poly(vinyl methyl ether); p01y(vinyl
methyl ether: maleic anhydride), sold under the trade name GANTREZ (available from
International Specialty ts); p01y(ether polyols), such as p01y(propylene glycol)
and the like, such as those sold under the trade name SANNIX (available from Sanyo
Chemical Industries); copolymers f, and the like. Copolymers ofthese and alkyl
(meth)acrylate esters or vinyl esters are also le. Gums such as those derived from
okra and guar may also be used.
Still another suitable pressure—sensitive adhesive includes about 10% to about
80%, by weight, of an alkali soluble polymer; about 0 to about 30%, by weight, of a
poly(vinyl methyl ether); about 30% to about 70%, by , of a tackifying resin; and
about 5% to about 30%, by weight, of a suitable plasticizer. Still other examples of
le adhesives include HX 9236-01 or HX 9237-01 hot melt adhesives, which are
obtainable from AT0 Findley, Inc.
The adhesive layer used in the present ion may comprise hydrocolloids.
The hydrocolloid t used may be any substance that exhibits good performance in
this utilization, as for example, sodium carboxymethylcellulose, pectin, xanthan gum,
polysaccharides, sodium or calcium alginates, chitosan, seaweed extract (cageenan),
polyaspartic acid, polyglutamic acid, hyaluronic acid or salts and derivatives thereof,
among others.
Received by IPONZ 25 July 2012
Hydrocolloids, just as sodium ymethylcellulose and pectin, among
others, are agents that form gels as soon as they come into contact with the bodily
fluids from the wound. When used in adhesive bandages, these olloids are
combined with elastomers and/or adhesives. Preferably, the adhesive bandage should
e a humid environment suitable for acceleration ofthe healing, but without
saturation or cicatrisation.
Pectin is a complex-structure polysaccharide extracted from vegetable species,
for example, peels from citric fruits or apple pulp, which has a highly hydrophilic
structure. As a , pectin associates easily with the water molecules of the bodily
fluids from the wound, forming a viscous gel on the injury bed. Its chemical similarity
with alginates causes the physical properties of tion and gel formation to
resemble each other.
Carboxymethylcellulo se, in turn, is a cellulose derivative formed by reaction of
cellulose with alkalis, such as, for example, sodium, potassium, calcium, etc.,
hydroxide. It is the nature of combined alkali that imparts the ionic characteristic of
carboxymethylcellulose. When sodium hydroxide is used, sodium
carboxymethylcellulose is formed. Just as in the case of pectin, carboxymethylcellulose
dissolves rapidly in the water coming from the liquids that emanate from the wound,
forming a gel on the wound with controlled ity.
As an additional advantage ofthe use ofhydrocolloids, it should be noted that
both pectin and carboxymethylcellulose form a gel with acidic teristics (pH of
about 4), fimctioning as a bactericidal agent.
The adhesive element used may be any conventional adhesive know for such
use, as for example pressure acrylic adhesives, among others. Additionally, such an
adhesive may contain a resin for increasing on, a cohesion increasing agent, an
absorption agent, preferably a polyacrylate superabsorbent, a polyacrylate salt
superabsorbent or a mixture thereof, a plasticizer and optionally a pigment. The
adhesive layer may further be configured in discontinuous patterns, arranged on the
e of the backing layer in lines, screen, spray or any other pattern which a person
skilled in the art tands to be discontinuous.
FIGS. 1 and 2a illustrate a first embodiment of an adhesive bandage of the
t invention. Adhesive bandage 10 comprises backing layer 20 having first surface
Received by IPONZ 25 July 2012
22 and opposing second surface 24 and a core body bounded by first 22 and second 24
surfaces. Adhesive layer 30 is disposed on at least a portion of second surface 24 of
backing layer 20. FIGS. 1 and 2a show adhesive layer 30 disposed on the ty of
second surface 24 ofbacking layer 20. Absorbent pad 40 is disposed on adhesive layer
such that absorbent pad 40 is associated with, e.g. by adhesive bonding, backing
layer 20. Mile adhesive layer 30 is shown covering the entirety of second surface 24
ing layer 20, it is to be understood that the adhesive layer may be disposed on a
portion of the second surface of the backing layer, provided that the amount of adhesive
applied, the location of the adhesive layer on the backing layer and the surface area of
the n of the second surface d by the adhesive layer is sufficient to associate
the ent pad to the backing layer, as discussed herein above, and to adhere the
bandage to the skin.
is an embodiment similar to that depicted in FIGS. 1 and 2a, except that
the first surface of absorbent pad 40 comprises covering layer 43 affixed o.
Covering layer 43 is applied to absorbent pad 40 prior to embossing, such that the
k of interconnecting channels is recessed and visible in covering layer 43.
rates a View of absorbent pad 40 as shown in as viewed
perpendicular to second surface 24 of absorbent pad 40. Pad 40 comprises tufted
regions 44 nded and ted by a network of interconnecting channels 46
recessed in second surface 42 ofpad 40, thus providing a first ment of a
densification pattern, e. g. a hexagon, used in bandages of the present invention.
is a cross—sectional side view of absorbent pad 40 taken along line 3b——-
3b of Absorbent pad 40 has first surface 41, second surface 42, core body 45, a
ity of tufted regions 44, and a network of interconnecting channels 46 recessed in
second surface 42 ofpad 40. The thickness (tt) of absorbent pad 40 is defined by the
distance between first 41 and second 42 surfaces of absorbent pad 40.
Tufted regions 44 have a thickness of tt and a substantially uniform first density.
As shown, first and second surfaces of tufted regions 44 coincide with first 41 and
second 42 surfaces of pad 40. As such, the thickness of pad 40 and tufted regions 44 are
the same. onnecting channels 46 have channel sidewalls 47 extending away from
second surface 42 and into core body 45 of absorbent pad 40 and terminating at first
surface 48a of channel base region 48 extending between channel sidewalls 47.
Channel base regions 48 have a thickness (tc) defined by the distance between first
Received by IPONZ 25 July 2012
surface 48a and second surface 48b of base region 48 and a substantially uniform
second density greater than the substantially uniform first density oftufied regions 44.
As used herein, the terms “low y, intermediate density, and high density” are
relative terms that are used in comparison to each other and unless specifically
quantified , are not intended to refer to any specific density or any degree of
density.
is a cross—sectional side view of a second embodiment of an ent
pad used in bandages ofthe present invention. In this embodiment, absorbent pad 80
has first surface 81, second surface 82 comprising a ng layer affixed thereto, core
body 85, tufted regions 84, and interconnecting channels 86 recessed in second surface
82. The thickness (t1) of absorbent pad 80 is defined by the distance between first 81
and second 82 surfaces of absorbent pad 80. Tufted s 84 have a thickness of tt
and a substantially uniform first density. Interconnecting channels 86 recessed in
second pad surface 82 have channel sidewalls 87 extending away from second pad
surface 82 and into core body 85 of absorbent pad 80 and ating at first surface
88a of channel base region 88 extending between channel lls 87.
Interconnecting channels 83 recessed in first pad surface 81 have channel sidewalls 89
extending away from first pad e 81 and into core body 85 of absorbent pad 80
and terminating at second surface 88b of channel base region 88 extending between
channel sidewalls 89. Channel base regions 88 have a thickness (tc) defined by the
distance between first 88a and second 88b surfaces of channel base region 88 and a
substantially uniform second density greater than the substantially uniform first density
of tufted regions 84.
FIGS. 4b—4d are embodiments ofbandages ofthe present invention comprising
absorbent pad 80 depicted in . As shown in , absorbent pad 80 is
associated to backing layer 90 via adhesive layer 92. Interconnecting ls 83 and
tufted regions 84 are shown, respectively. In this ment, the network of
onnected channels 83 may be e to the user through second surface 94 of
g layer 90, for e where backing layer 90 is transparent or translucent,
although such visibility is not required. As shown in , absorbent pad 80 is
associated to backing layer 90 via adhesive layer 92. Channels 83 and tufted regions 84
are shown, respectively. In this embodiment, backing layer 90 conforms to recessed
channels 83 such that backing layer 90 includes the network of interconnecting
Received by IPONZ 25 July 2012
ls 83 recessed in second surface 94 ofbacking layer 90. As such, the network of
interconnected channels 83 recessed in g layer 90 is Visible to the user.
is a View of the embodiment depicted in as viewed perpendicular to e 94
ofbacking layer 90. In this embodiment, the densification pattern formed by tufted
regions 84 and channels 83 is visible to the user.
represents an additional embodiment of a pad densification pattern of
absorbent pads used in bandages of the t invention. In absorbent pad 50
has tufted regions 54 separated by a network of recessed, interconnecting channels 56.
Tufted regions 54 have a diamond shape when viewed perpendicular to the second
e ofthe absorbent pad. Yet another embodiment of an ve bandage ofthe
present invention is shown in cross—sectional side View in Adhesive bandage
110 comprises backing layer 120 having a first surface 122 and opposing second
surface 124. Adhesive layer 130 is disposed on second surface 124 ofbacking layer
120. Intermediate layer 150 is disposed on adhesive layer 130 so as to achieve bonding
between backing layer 120 and intermediate layer 150. Absorbent pad 140 is associated
with intermediate layer 150.
Though shows adhesive layer 130 disposed on the entirety of second
surface 124 ing layer 120, it is to be understood that ve layer 130 may be
disposed on a portion of second surface 124 ofbacking layer 120, as discussed herein
above. Absorbent pad 140 is disposed on a portion of intermediate layer 150 and
associated with intermediate layer 150 so as to achieve bonding between ediate
layer 150 and absorbent pad 140, thus also associating pad 140 to backing layer 120 via
intermediate layer 150. The bond may be in the form of an adhesive, or may be any
other known means ofbonding, such as by ultrasonic welding. Though shows
absorbent pad 140 disposed on the ty of intermediate layer 150, it is to be
understood that absorbent pad 140 may be disposed on a portion of intermediate layer
150.
Absorbent pad 140 and intermediate layer 150 may have various shapes, 6.g.
rectangular, square, oval, circular, ovoid, oblong, etc, and be sized to cover less area
than backing layer 120 so that, in use, adhesive layer 130 is in contact with the user’s
skin, but preferably does not contact the wound surface.
Received by IPONZ 25 July 2012
The absorbent pad may be a fibrous matrix sing an organized network
selected from the group consisting of s, yarns, nets, laces, felts and nonwovens. A
preferred method of making the absorbent pad is known to one skilled in the art as the
wet lay process of forming nonwovens.
Embossing may be performed ultrasonically through an ultrasonic system which
includes a nip roll for ing tension to the web, an engrave/machined roll
constructed ofhardened steel, and an ultrasonic horn. The ultrasonic horn and
e/machined roll are set to a positioned so that the roll and horn would have no
gap ifthe material being embossed was not between the rolls. The web would have a
consistent and maintained tension, embossing the web with an ultrasonic system.
Alternatively, embossing may be med using heat and pressure through a
heated roll system which includes a nip roll for providing tension to the web, an
e/machined roll constructed ofhardened steel, and an anvil roll. Heat is applied
in this area to raise the temperature of the substrate. The anvil roll and
engrave/machined roll are set to a on so that the roll and anvil would have no gap
if the material being embossed was not between the rolls. The web would have a
consistent and maintained n, embossing the web with an engrave/machined roll
and anvil.
The process of manufacturing the adhesive bandage of the present invention
may be any of those conventionally known to produce adhesive bandages. The backing
layer, absorbent pad, and adhesive layer can be obtained by any methods available at
present. For example, an extrusion process may be used for obtaining the backing layer.
In the same way, the adhesive layer can be made in any known manner. A backing
layer as described herein is obtained and an adhesive layer as described herein is
applied to the second surface of the support layer. The absorbent pad is then ated
with the adhesive bonding layer, thus bonding the ent pad to the backing layer.
The adhesive bandages of the invention are ideally suited to deliver one or more
active ingredients such as therapeutics to the surface of the skin. When contained in the
adhesive bandages of the ion, one or more active ingredients may be contained
primarily or exclusively in the absorbent pad of the adhesive bandage. Illustrative
classes of active ingredients that may be delivered to the skin via the adhesive bandages
of the invention include, but are not limited to, antibiotics, sics, antipyretics,
Received by IPONZ 25 July 2012
antimicrobials, antiseptics, antiallergics, anti-acne, etics, anti—inflammatories,
hemostats, cosmetics, vitamins, vasodilators,‘emollients, pH regulators, antipruritics,
counterirritants, antihistamines and steroids. Specific active ingredients that may be
delivered to the skin via the dressings of the invention include chlorhexidine, neomycin
e, polymyxin—B sulfate, zinc bacitracin, benzalkonium de, yridinium
chloride, bupivacaine, tetracaine, cincaine, lidocaine, benzocaine, silver sulfadiazine,
hydrocortisone, metandienone, trypsin, tolazoline, heparin, pramoxine, aloe vera,
tretinoin, retinol, retinaldehyde, l, capsaicin, alpha hydroxy acids and vitamins
such as Vitamin E.
While various embodiments ofthe invention have been set forth above, it will
be apparent to those skilled in the art that various modifications and variations can be
made in the present invention without departing from the scope or spirit of the
ion. Thus, it is intended that the present invention cover such modifications and
variations as come within the scope of the appended claims and their lents.
E 1: Production of Embossed Pads and Bandages.
Absorbent pads were made from 3.7 oz/yd2 polypropylene (PP) and 3.7 oz/yd2
polyethylene thalate (PET) pad stock, respectively. The pads were embossed with
a hexagonal pattern of interconnecting channels. Embossing was performed at slower
and faster speeds. Some ofthe absorbent pads were then adhered to polyethylene
backing layers to form adhesive bandages. A total of four different pads and four
different bandages were formed.
The thickness of tufted regions (t1), the thickness of the channel base regions (to)
and the Width of the channel base regions (we) were measured optically using a
Mituoyo PH—A14 Profile Projector with a QM-Data 200. Specimens were razor cut
orthogonally to the hexagonal pattern. Five measurements were taken for each of the
four different pads and four different bandages formed. The depth of the channel base
regions (he) were calculated based upon the thickness of the tufted and l base
Table 1 shows the maximum and minimum thickness of tufted regions (t1), the
m and minimum thickness of the channel base regions (tc), the width of the
channel base s (we), and the depth of the channel base regions (he).
Received by IPONZ 25 July 2012
Table 1: Dimensions of Embossed Pads and Bandages.
Material
PP Pad (slow)
PP Pad (fast)
PET Pad 1.104
(slow)
PET Pad 0.469
(fast)
PP Bandage 0.469 0.725
(slow)
PP Bandage 0.356 0.769
(fast)
PET Bandage 0.302 1.167
(slow)
PET Bandage 0.928 1.165 1.097 1.133 0.323 0.205
(fast)
EXAMPLE 2: Fluid tion of Embossed and Non-Embossed Pads:
Absorbent 1 inch by 1 inch pads were made from 3.7 oz/yd2 polypropylene (PP)
non-woven pad stock and 3.7 oz/yd2 polyethylene terephthalate (PET) non-woven pad
stock, as in Example 1. Some absorbent pads were embossed at a speed intermediate to
those of Example 1 with a hexagonal pattern of interconnecting channels for testing. A
total of four different pads were tested.
Each pad was placed over a SOuL drop of synthetic blood having Viscosity less
than 50,000 centipoise. A glass slide and weight (200 grams) were placed on each pad
for 10 seconds. After 3 s, the blood spread area was then measured using image
analysis and recorded as the percentage of the pad area. Three specimens were
measured for each sample.
Table 2 shows the spread area for pads having a network of interconnecting
ls embossed into the surface versus non—embossed pads.
Received by IPONZ 25 July 2012
Table 2: Fluid Spread Area.
Specimen
PP non-embossed 21
PP embossed
PET non—embossed
The table shows that embossing absorbent pads according to the t
invention significantly increases the spread area of the synthetic blood.
EXAMPLE 3: Ointment Spread of Embossed and Non-Embossed Pads.
ent pads made according to Example 2 were tested for Ointment Spread
as described below.
A tinted anti-bacterial ointment (0.1 gram) was placed on each pad. A glass
slide and weight (200 grams) were placed on each pad forlO seconds. The ointment
spread area was then measured using image analysis and recorded as the percentage of
the pad area. Three specimens were measured for each .
Table 3 shows the spread area for pads having a network of interconnecting
channels embossed into the surface versus non-embossed pads.
Table 3: Ointment Spread Area.
Specimen
PP non-embossed
PP embossed -I_
PET non-embossed 65 o 6
1 PET embossed I 50 1 7:2 ]
The table shows that embossing absorbent pads according to the present
invention significantly decreases the spread area of the tinted ointment.
EXAMPLE 4: Fluid Absorption of Embossed and Non-Embossed Pads on
Adhesive Bandages.
Absorbent pads made according to Example 2 were placed on a polyethylene
laminate backing layer comprising a pressure sensitive ve applied thereto. The
bandages were tested for fluid tion as described below.
Each bandage was placed over a 30uL drop of synthetic blood. A glass slide
and weight (200 grams) were placed on each e for 10 seconds. After 3 minutes,
Received by IPONZ 25 July 2012
the blood spread area was then ed using image analysis and recorded as the
percentage ofthe bandage area. Three specimens were measured for each sample and
compared to a comparative bandage that did not include a pad having a network of
interconnecting channels embossed therein. Table 4 shows the spread area for adhesive
bandages according to the present invention versus comparative bandages that do not
include a pad having a network of interconnecting ls embossed n.
Table 4: Fluid Spread area.
Specimen I Spread Area % I Std. Dev.
Control Bandage with bossed Pad I 27 I 1.6
Bandage with PET Embossed Pad I 68 I 3.1
Bandage with PP Embossed Pad I 78 I 5.3
The table shows that embossing absorbent pads on adhesive bandages ing
to the present invention significantly increases the spread area of the tic blood
compared to the comparative bandage.
E 5: Ointment Spread of Embossed and Non-Embossed Pads on
Adhesive Bandages.
Absorbent pads made according to Example 2 were placed on a polyethylene
laminate backing layer comprising a pressure sensitive adhesive applied thereto. The
bandages were tested for nt spread area as described below.
A tinted anti-bacterial ointment (0.05g) was placed on each bandage. A glass
slide and weight (200 grams) were placed on each bandage. Alter 10 seconds, the
ointment spread area was then measured using image analysis, and recorded as the
percentage ofthe pad area. Three specimens were measured for each sample and
compared to a comparative bandage that did not include a pad having a k of
interconnecting channels embossed therein. Table 5 shows the spread area for adhesive
bandages according to the present invention versus comparative adhesive bandages
utilizing pads that do not have a network of interconnecting channels embossed therein.
Table 5: Ointment Spread area.
Spread Area %
Control Bandage with non-embossed Pad 54
Bandage with PET Embossed Pad I 45 .
I e with PP Embossed Pad I 26 I 1.8
Received by IPONZ 25 July 2012
The table shows that embossing pads on bandages according to the present
ion significantly decreases the spread area of the tinted ointment versus the
comparative adhesive bandage that does not include a pad having a network of
interconnecting channels embossed therein.
Received by IPONZ 25 July 2012
Claims (17)
1. An adhesive bandage for application to ons or cuts in the skin, comprising: a g layer comprising a first surface and a second surface opposite said first surface, an adhesive layer applied to at least a portion of said second surface of said backing layer; and an ent pad associated with said backing layer, said absorbent pad 10 comprising, a first surface facing said second surface of said backing layer and having a first surface area, a second surface opposite said first surface and having a second surface area; and 15 a core body bounded by said first and second surfaces; said absorbent pad comprising a plurality of tufted regions surrounded and separated by a first network of onnecting linear channels recessed in said second surface of said absorbent pad, said channels comprising channel sidewalls extending away from said second surface and into said core body of 20 said absorbent pad and terminating in a first surface of a channel base region extending between said channel sidewalls, wherein the absorbent pad is free of slits or perforations mly distributed throughout the absorbent pad that would allow the ve layer to contact the wound surface; 25 wherein the shape of each of said tufted regions is a polygon having from four to eight sides, said tufted regions have a substantially uniform first y, said channel base regions have a substantially m second density greater than said substantially uniform first density of said tufted s and said network of channels is Visible. 30
2. The bandage of claim 1 wherein said second density of said channel base region is about 12 times or less greater than said first density of said tufted regions. Received by IPONZ 25 July 2012
3. The bandage of claim 1 wherein said substantially uniform second density of said channel base region is from about 0.11 g/cc to about 0.96 g/cc.
4. The bandage of claim 1 wherein said substantially uniform first density of said tufted regions is from about 0.082 g/cc to about 0.17 g/cc.
5. The bandage of claim 1 wherein said channels have a width of from about 0.2 to about 06 millimeters and a depth from about 0.02 to about 2 millimeters. 10
6. The bandage of claim 1 wherein said absorbable pad is not degradable in water.
7. The bandage of claim 1 wherein said first network of onnecting channels comprises from about 5 to about 20 percent of said second surface area of said second surface of said absorbent pad.
8. The bandage of claim 1 wherein said ent pad comprises fibers selected from the group consisting of natural and synthetic materials.
9. The bandage of claim 1 further comprising an intermediate layer ed 20 n said g layer and said absorbent pad.
10. The bandage of claim 1 wherein said shape of said tufted regions is hexagonal, said substantially uniform y of said channel base region is from about 0.11 g/cc to about 0.96 g/cc, said substantially m density of said tufted regions is from about 25 0.086 g/cc to about 0.17 g/cc, and said channels have a width of from about 0.2 to about 0.6 millimeters and a depth from about 0.02 to about 2 millimeters.
11. The bandage of claim 1 further comprising a second network of interconnecting channels ed in said first surface of said ent pad, said tufted regions being 30 surrounded and separated by said second network of interconnecting channels recessed in said first surface of said absorbent pad, said channels in said second network of interconnecting channels comprising channel sidewalls extending away from said first surface and into said core body of said absorbent pad and terminating in a second Received by IPONZ 25 July 2012 surface of said channel base region opposite said first surface of said channel base region and extending n said channel sidewalls of said second network.
12. The bandage of claim 1 wherein said thickness of said absorbent pad is from about 0.3 millimeters to about 2.5 millimeters.
13. The bandage of claim 1 wherein the thickness of said base channel region is from about 0.1 millimeters to about 1.5 millimeters. 10
14. The bandage of claim 11 wherein said second network of interconnecting channels is visible.
15. The bandage of claim 1 n said second surface of said ent pad comprises a covering layer.
16. The bandage of claim 11 wherein said second surface of said absorbent pad comprises a covering layer.
17. A bandage according to claim 1 substantially as herein described with reference 20 to any e thereof and/or any embodiment shown in the anying drawings.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/036,499 | 2011-02-28 | ||
US13/036,499 US20120220974A1 (en) | 2011-02-28 | 2011-02-28 | Adhesive bandage |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ598439A NZ598439A (en) | 2012-08-31 |
NZ598439B true NZ598439B (en) | 2012-12-11 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012201127B2 (en) | Adhesive bandage | |
AU2012201128B2 (en) | Adhesive bandage | |
EP1880840B1 (en) | Absorbent article | |
US8058499B2 (en) | Absorbent wound dressing containing a hydrogel layer | |
US20110077608A1 (en) | Cushioned adhesive bandage | |
CN107007867A (en) | Hemostatic material | |
CN107625582A (en) | Wound dressing, its preparation method and its application with sandwich construction | |
EP3288510B1 (en) | Wound dressing | |
US20090156974A1 (en) | Absorbent wound care device | |
EP3288512B1 (en) | Wound dressing | |
US20170128270A1 (en) | Wound dressing | |
ZA200305540B (en) | Absorbent article. | |
US20020115972A1 (en) | Absorbent article | |
NZ598439B (en) | Adhesive bandage | |
NZ598438B (en) | Adhesive bandage |